{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:05:15Z","timestamp":1790139915113,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.numecd.2026.104994","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:40:56Z","timestamp":1788849656000},"page":"104994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis"],"prefix":"10.1016","author":[{"given":"Ahmed J.","family":"AlAraibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema Naser","family":"Shakeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Alqatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu-baker","family":"Sharafeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-3917","authenticated-orcid":false,"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.numecd.2026.104994_bib1","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.numecd.2026.104994_bib2","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/j.orcp.2013.12.005","article-title":"Mechanisms of heart failure in obesity","volume":"8","author":"Ebong","year":"2014","journal-title":"Obes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.numecd.2026.104994_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.15386\/mpr-1884","article-title":"Metabolic syndrome and heart failure: mechanism and management","volume":"94","author":"Purwowiyoto","year":"2021","journal-title":"Med Pharm Rep"},{"issue":"1","key":"10.1016\/j.numecd.2026.104994_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12872-025-05029-4","article-title":"Trends in obesity and heart failure-related mortality in middle-aged and young adult populations of the United States, 1999-2022","volume":"25","author":"Abdul Jabbar","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"10.1016\/j.numecd.2026.104994_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.numecd.2026.104994_bib6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.numecd.2026.104994_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174092","article-title":"The effects of dual GLP-1\/GIP receptor agonism on Glucagon Secretion-A review","volume":"20","author":"Mathiesen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"15","key":"10.1016\/j.numecd.2026.104994_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.numecd.2026.104994_bib10","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.numecd.2026.104994_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on Chronic Kidney Disease in Patients with Type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.numecd.2026.104994_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24283","article-title":"Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"47","author":"Rehman","year":"2024","journal-title":"Clin Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2026.104994_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City cardiomyopathy questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"10.1016\/j.numecd.2026.104994_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3349\/ymj.2010.51.2.151","article-title":"Interpretation and use of natriuretic peptides in non-congestive heart failure settings","volume":"51","author":"Tsai","year":"2010","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.numecd.2026.104994_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol"},{"issue":"16","key":"10.1016\/j.numecd.2026.104994_bib16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.numecd.2026.104994_bib17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.numecd.2026.104994_bib18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.numecd.2026.104994_bib27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.numecd.2026.104994_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2026.104994_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2026.104994_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.numecd.2026.104994_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2026.104994_bib23","article-title":"Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obes Pillars"},{"issue":"24","key":"10.1016\/j.numecd.2026.104994_bib24","article-title":"Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database","volume":"14","author":"Osei","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.numecd.2026.104994_bib25","article-title":"GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.numecd.2026.104994_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"10.1016\/j.numecd.2026.104994_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.12.004","article-title":"Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction","volume":"6","author":"Hellenkamp","year":"2025","journal-title":"Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326004564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326004564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:26:36Z","timestamp":1790137596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326004564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S0939475326004564"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104994","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104994"}}